PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.10
Ask: 3.40
Change: -0.10 (-2.99%)
Spread: 0.30 (9.677%)
Open: 3.35
High: 3.35
Low: 3.25
Prev. Close: 3.35
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BROKER RATINGS SUMMARY: Jefferies Starts Metro Bank With Buy Rating

Thu, 10th Mar 2016 09:33

LONDON (Alliance News) - The following shares received analyst recommendations Thursday morning and Wednesday:
----------
FTSE 100
----------
GOLDMAN CUTS ROLLS-ROYCE TO 'NEUTRAL' ('BUY') - TARGET 725 (711) PENCE
----------
PANMURE RAISES RSA INSURANCE TO 'HOLD' ('SELL') - TARGET 428 (385) PENCE
----------
CITIGROUP CUTS NEXT PRICE TARGET TO 7,400 (7,800) PENCE
----------
TRADERS: KEPLER CHEUVREUX STARTS BP WITH 'REDUCE'
----------
JEFFERIES RAISES WHITBREAD TO 'HOLD' ('UNDERPERFORM') - TARGET 3,600 (4,100)P
----------
DEUTSCHE BANK RAISES PRUDENTIAL PRICE TARGET TO 1620 (1565) PENCE - 'HOLD'
----------
BERNSTEIN CUTS RBS TO 'MARKET-PERFORM' ('OUTPERFORM') - TARGET 230 (450) PENCE
----------
TRADERS: MACQUARIE RAISES INTU PROPERTIES TO 'OUTPERFORM' ('NEUTRAL')
----------
MORGAN STANLEY CUTS ASTRAZENECA PRICE TARGET TO 5000 (5300) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS SCHRODERS PRICE TARGET TO 3,275 (3,350) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS ASHTEAD GROUP PRICE TARGET TO 1,140 (1,240) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES SSE TO 'OVERWEIGHT' ('UNDERWEIGHT') - TARGET 1,550 (1,280) PENCE
----------
JPMORGAN RAISES CENTRICA TO 'NEUTRAL' ('UNDERWEIGHT') - TARGET 230 PENCE
----------
FTSE 250
----------
CITIGROUP CUTS RESTAURANT GROUP TO 'SELL' ('NEUTRAL') - TARGET 370 (575)P
----------
GOLDMAN CUTS RESTAURANT GROUP TO 'NEUTRAL' ('CONVICTION BUY')
----------
BERENBERG CUTS RESTAURANT GROUP TO 'HOLD' ('BUY') - TARGET 550 (750) PENCE
----------
BARCLAYS CUTS RESTAURANT GROUP PRICE TARGET TO 475 (760) PENCE - 'EQUAL WEIGHT'
----------
BARCLAYS CUTS G4S TO 'EQUAL WEIGHT' ('OVERWEIGHT') - TARGET 200 (310) PENCE
----------
BARCLAYS CUTS CLOSE BROTHERS PRICE TARGET TO 1,300 (1,375)P - 'EQUAL WEIGHT'
----------
BARCLAYS RAISES CAIRN ENERGY PRICE TARGET TO 190 (180) PENCE - 'EQUAL WEIGHT'
----------
DEUTSCHE BANK RAISES CAIRN ENERGY PRICE TARGET TO 220 (200) PENCE - 'BUY'
----------
EXANE BNP RAISES CAIRN ENERGY PRICE TARGET TO 201 (176) PENCE - 'OUTPERFORM'
----------
EXANE BNP CUTS G4S PRICE TARGET TO 180 (240) PENCE - 'NEUTRAL'
----------
RBC CAPITAL CUTS G4S PRICE TARGET TO 170 (190) PENCE - 'UNDERPERFORM'
----------
GOLDMAN RAISES AUTO TRADER GROUP TO 'BUY' ('NEUTRAL') - TARGET 443 (415) PENCE
----------
TRADERS: PEEL HUNT RAISES SAVILLS TO 'ADD' ('HOLD')
----------
LIBERUM CUTS COBHAM PRICE TARGET TO 270 (330) PENCE - 'BUY'
----------
HSBC RAISES PETROFAC PRICE TARGET TO 1,150 (900) PENCE - 'BUY'
----------
Liberum Ups Laird Target To 350p From 325p, Keeps Hold
----------
SHORE CAPITAL CUTS RATHBONE BROS TO 'HOLD' ('BUY') - TARGET 2350 (2840) PENCE
----------
JPMORGAN CUTS DRAX GROUP PRICE TARGET TO 360 (370) PENCE - 'NEUTRAL'
----------
JPMORGAN CUTS CLOSE BROTHERS PRICE TARGET TO 1,600 (1,630) PENCE - 'OVERWEIGHT'
----------
JPMORGAN RAISES ESURE GROUP PRICE TARGET TO 287 (286) PENCE - 'OVERWEIGHT'
----------
JPMORGAN CUTS DRAX GROUP PRICE TARGET TO 260 (370) PENCE - 'NEUTRAL'
----------
MORGAN STANLEY RAISES WILLIAM HILL PRICE TARGET TO 425 (400)P - 'EQUAL-WEIGHT'
----------
MORGAN STANLEY CUTS UNITE GROUP PRICE TARGET TO 770 (780) PENCE - 'OVERWEIGHT'
----------
MAIN MARKET AND AIM
----------
Jefferies Initiates Metro Bank With Buy, 3,000.00p Price Target
----------
PANMURE ADDS PANTHEON RESOURCES TO CONVICTION LIST - 'BUY' - TARGET 170 PENCE
----------
PANMURE RAISES HILL & SMITH PRICE TARGET TO 950 (850) PENCE - 'BUY'
----------
PANMURE RAISES ALLERGY THERAPEUTICS PRICE TARGET TO 53 (51) PENCE - 'BUY'
----------
RBC CAPITAL CUTS FIRESTONE DIAMONDS TARGET TO 35 (40)P - 'SECTOR PERFORM'
----------
RBC CAPITAL RAISES NOVAE GROUP PRICE TARGET TO 975 (950) PENCE - 'OUTPERFORM'
----------
RBC CAPITAL CUTS GEM DIAMONDS PRICE TARGET TO 170 (190) PENCE - 'OUTPERFORM'
----------
RBC CAPITAL CUTS GENEL ENERGY TO 'SECTOR PERFORM' ('OUTPERFORM') CUTS PRICE TARGET TO 115 (400) PENCE
----------
Nomura Ups Stock Spirits Group Target To 150p From 140p, Keeps Neutral
----------
BERENBERG RAISES TYMAN PRICE TARGET TO 330 (310) PENCE - 'BUY'
----------
LIBERUM RAISES TYMAN PRICE TARGET TO 335 (310) PENCE - 'BUY'
----------
UBS RAISES HOCHSCHILD MINING PRICE TARGET TO 120 (80) PENCE - 'BUY'
----------
BERENBERG RAISES NICHOLS PRICE TARGET TO 1,475 (1,450) PENCE - 'BUY'
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
26 Oct 2020 14:17

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

IN BRIEF: Allergy Therapeutics Kicks Off Grass Allergy Therapy Study

Read more
26 Oct 2020 13:37

Allergy Therapeutics screens first patients in grass pollen study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics announced the screening of the first patient in its exploratory field study 'G309', to evaluate the efficacy and safety of 'Grass MATA MPL' in subjects with seasonal allergic rhinitis or rhinoconjunctivitis induced by grass pollen exposure.

Read more
23 Sep 2020 14:02

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

UK EARNINGS SUMMARY: LoopUp Swings To Profit On Work-From-Home Boost

Read more
4 Sep 2020 19:39

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

IN BRIEF: Allergy Therapeutics Secures VLP Technology Platform

Read more
3 Sep 2020 15:31

Allergy Therapeutics signs new vaccine deal with Saliba and DeepVax

(Sharecast News) - Biotechnology company Allergy Therapeutics announced further investment in virus-like particle (VLP) technology for applications beyond the allergy immunotherapy field on Thursday.

Read more
15 Jul 2020 11:47

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Read more
15 Jul 2020 09:03

Allergy Therapeutics revenues grow despite Covid-19 disruption

(Sharecast News) - Biotechnology company Allergy Therapeutics reported a "strong" full-year performance on Wednesday despite challenges stemming from the Covid-19 pandemic.

Read more
9 Jul 2020 21:19

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

IN BRIEF: Allergy Therapeutics To Recommence Birch B301 Trial

Read more
9 Jul 2020 16:26

Allergy Therapeutics pleased with invalidation of B301 trial data

(Sharecast News) - Biotechnology company Allergy Therapeutics announced the outcome of scientific advice from the German Regulatory Authority, the Paul Ehrlich Institute (PEI), over invalidation of the primary endpoint data of the Birch MATA MPL pivotal phase 3 clinical trial, or 'B301', on Thursday.

Read more
24 Jun 2020 11:53

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Allergy Therapeutics Anticipates Profit Ahead Of Expectations

Read more
24 Jun 2020 10:12

Allergy Therapeutics on track to 'significantly' exceed FY expectations

(Sharecast News) - Biotechnology company Allergy Therapeutics said on Wednesday that its 2020 trading performance was on track to exceed market expectations.

Read more
4 Mar 2020 10:46

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Allergy Therapeutics Well-Placed Despite Regulatory "Challenge"

Read more
26 Feb 2020 16:15

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
16 Jan 2020 13:28

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Allergy Therapeutics Outlook Confident As Revenue Rises In First Half

Read more
26 Nov 2019 14:15

Allergy Therapeutics to take 'stepwise approach' to upcoming grass study

(Sharecast News) - Commercial biotechnology company Allergy Therapeutics updated the market on its grass MATA MPL phase 3 study, due to start in autumn 2020, on Tuesday, reporting that following further investigation of the phase 3 birch MATA MPL study, the upcoming grass study would now take a 'stepwise approach'.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.